Updates are available Correction dated 2024-03-26
Click to view Correction: https://doi.org/10.1186/s40364-024-00582-0
-
Authors
Ganci, Federica
Allegretti, Matteo
Frascolla, Carlotta
Spinella, Francesca
Rollo, Francesca
Sacconi, Andrea
Valentina, Pascale De
Palcau, Alina Catalina
Manciocco, Valentina
Vescovo, Mariavittoria
Cotroneo, Ettore
Blandino, Francesca
Benevolo, Maria
Covello, Renato
Muti, Paola
Strano, Sabrina
Vidiri, Antonello
Fontemaggi, Giulia
Pellini, Raul
Blandino, Giovanni
-
Funding
Funding for this research was provided by:
intramural fundings from IRCCS Regina Elena National Cancer Institute
Ministero della Salute (H53C22001150001, H53C22001150001, H53C22001150001)
Alleanza Contro il Cancro (IG #20616)
- License Information
-
More Information
Article History
Received: 16 October 2023
Accepted: 15 February 2024
First Online: 5 March 2024
Change Date: 26 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40364-024-00582-0
Declarations
:
: The present work was carried out at the IRCCS Regina Elena National Cancer Institute. Authorization from the Institutional Ethic Review Board (RS868/16) was obtained, and a written informed consent was collected from all human subjects involved in this analysis (<i>n</i> = 69).
: Not applicable.
: The authors declare that they have no known competing financial interests or personal relationships that could influence this paper. However, it has to be stated that both the custom mutational panel including the full coding sequence of <i>TP53, CDKN2A</i> and <i>FAT1</i> and the 4-microRNAs signature have been patented by B.G., G.F., S.F., (#102020000017896) and by B.G., G.F., M.V and P.R., (#102020000019024), respectively.
